Furthermore, that study reported T cell specific reactivity against CLL cells, while also showing that immunization of Eμ-TCL1 mice with BcR IG-derived peptides led to anti-leukemic T cell responses, implying that targeted T cell immunotherapy against the clonotypic BcR IG represents an appealing treatment option (28). The gene discussed is BCR; the disease is B-cell chronic lymphocytic leukemia.